 MINNEAPOLIS, Feb. 17, 2021 GLOBE NEWSWIRE -- Predictive Oncology NASDAQ: POAI, a knowledge-driven company focused on applying artificial intelligence AI to personalized medicine and drug discovery, announced today that the products of its wholly owned subsidiary, TumorGenesis, aided researchers in the understanding of how ovarian cancer cells migrate outside the abdominal cavity. The research, completed by a top-tier laboratory in Massachusetts, used TumorGenesiss media to capture, culture, and identify how these cells break through the protective lining in the abdomen, called the omentum or abdominal membrane. 